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1. Introduction 
Affinity separation of neural membranes or mem- 
brane constituents by the use of receptor probes 
could well be developed into an important tool in 
studying the complex structure of the CNS. This idea 
was also suggested in [ 11. As a probe of opioid recep- 
tors, a bifunctional Leu’-enkephalin analogue was 
thought to be plausible. A ‘sandwich’ technique was 
preferred to direct coupling to a separation matrix, 
enabling versatility of possible separation methods. 
Leu’enkephalin was coupled to biotin via two 
spacers of different lengths: Lys and Gly-Gly-Lys. 
The biotin-avidin interaction (K,<10-14 M) as a 
second coupling function has already been used in 
other systems [2-41 as suggested in [5]. Both anal- 
ogues had the same ZC,,-, value against (D-Ala*-Leu’)- 
[3H]enkephalin as indicator ligand in receptor-bind- 
ing experiments. The affinities of both derivatives 
were lowered in the presence of avidin, but the 
decrease was less for the ligand with the longer spacer, 
indicating steric hindrance by avidin. 
2. Materials and methods 
(t)-Biotin and avidin (lo- 12 units/mg) were pur- 
chased from Sigma, amino acid derivatives and pep- 
tides from Bachem, 1 ,l’-carbonyldiimidazole and 
N-hydroxysuccinimide from Aldrich-Europe, thin- 
layer chromatography plates from Merck, CPK space- 
filling molecule models from Schwarz/Mann. The 
iodinated precursor of (D-Ala2-Leu5)-[3H]enkephalin 
was synthesised by Ulf Ragnarsson, (Department of 
Abbreviations: DMF, dimethylformamide; CDI, l,l’-car- 
bonyldiimidazole; TFA, trifluoroacetic acid; DCCI, dicy- 
clohexylcarbodiimide; HBT, l-hydroxybenzotriazole; HPLC, 
high-pressure liquid chromatography 
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Biochemistry, Uppsala University) and tritiated at 
The Radiochemical Centre, Amersham (spec. act. 33 
Ci/mmol). Biotin measurement was done colorimet- 
rically according to [6]. Amino acid analysis was per- 
formed at the Department of ‘Biochemistry, Uppsala 
University. HPLC was performed on a Whatman M9 
semi-preparative Partisil ODS column, using 30 min 
linear gradients of 30-80% methanol containing 0.1% 
ammonium acetate, at pH 6.2. Synthesis progress was 
followed by thin-layer chromatography. 
2.1. Synthesis of ((+)-biotinyllysyl’l-Leu5-enkephalin 
amide (BL) 
N(Y-Boc-lysine amide (I): NHs gas was bubbled 
through NQ-Boc-NE-Z-lysine-AJ-hydroxysuccinim- 
ide ester in DMF for 2 h and the mixture left at 
4°C overnight. The solvent was removed and the 
product recrystallized from ethanol-water. Z was 
removed by catalytic hydrogenation with Pd-coal 
in methanol and (I) was recrystallized from etha- 
nol-water . 
(+)-Biotinyl-N-hydroxysuccinimide ester (II): This 
compound was synthesised as in [7] using CD1 and 
N-hydroxysuccinimide, and recrystallized from 
2-propanol. 
NE-Biotinyllysine amide (III): (I) t (II) were stirred 
overnight at 4°C in DMF. The product was puri- 
fied by recrystallization from 2-propanbl and by 
adsorption chromatography on silica gel for 
removal of contaminating A@-Boc-lysine amide, 
and finally by DEAE-Sephadex chromatography 
subsequent to removal of Boc by treatment with 
TFA t anisole. 
[(+)-Biotinyllysyl’]-Leu’-enkephalin amide (BL): 
Boc-Tyr-Gly-Gly-Phe-Leu + (III) were cou- 
pled in DMF by CDI. Boc was removed by treat- 
ment with TFA + anisole after precipitation of the 
reaction mixture by dilution with water. Purifica- 
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tion was achieved by HPLC. The product’s com- 
position was verified by biotin measurement and 
amino acid analysis. 
2.2. Synthesis of I(+)-biotiny~iglycyllysyls]Leu5- 
enkephalin amide (BGL) 
N(Y-Boc-NE-diglycyllysine amide (IV): Z-Gly-Gly was 
dissolved in DMF, equimolar CD1 added and 
stirred at room temperature for 1 h after CO2 evo- 
lution had ceased, whereupon (I) was added. Stir- 
ring was continued overnight at 4°C. The product 
was recrystallized from ethanol. Z was removed by 
catalytic hydrogenation. 
fl-(+)-Biotinyldiglycyllysine amide (V): (II) t (IV) 
were dissolved in DMF and stirred overnight at 
4°C. The product was recrystallized 3 times from 
ethanol at -20°C and Boc was removed with 
TFA t anisole. 
[(t)-Biotinyldiglycyllysy15]-LeuS-enkephalin amide 
(BGL): Boc-Tyr-Gly-Gly-Phe-Leu t (V) were 
coupled in DMF by DCCI t HBT and triethylamine. 
BGL was purified by HPLC and verified by biotin 
measurement and amino acid analysis. 
2.3. Binding studies 
Rat brain synaptic plasma membrane (SPM) prep- 
arations and binding studies were performed essen- 
tially as in [8]. SPM (200 ~1) in physiological Hepes 
buffer pH 7.4 (l-2 mg protein/ml) was incubated for 
1.5 min at 25’C with radioligand (to give 0.35 nM 
final cont.), competing ligand and eventual additions 
to 425 ~1 total vol. The incubation was terminated by 
cooling to O’C and centrifugation for 5 min on a 
Beckman Microfuge. Non-specific binding of radio- 
ligand measured as binding in the presence of lo-’ M 
LeuSenkephalin (0% in displacement curves) was 
subtracted from all experimental values. When avidin 
was to be added, dilutions were made from an initial 
solution of bifunctional ligand t avidin in calculated 
molar ratios bifunctional 1igand:avidin of 4: 1 (most 
experiments) or 1: 1. In a control experiment, biotin 
binding sites of avidin were blocked by preincubation 
with a 25% calculated excess of (t)-biotin. 
3. Results 
The two bifunctional ligands were tested in 
receptor displacement assays against (D-Ala’-LeuS)- 
[3H]enkephalin, a metabolically stable analogue of 
LeuS-enkephalin, as shown in fig.1. Both BL and BGL 
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Fig.1. Displacement curves of Leu*-enkephalin (0); BL (A); 
BGL (a); BL + avidin 4: 1 (A); and BGL + avidin 4: 1 (m); 
using (D-AlaZ-Leu5)-[3H]enkephalin as indicator @and. 
had an lCsO value of 5 X 10m8 M in the absence of 
avidin, to be compared with 5 X 10m9 M for the 
parent compound. In the presence of avidin, however, 
the affinities decreased, the& of BL + avidin chang- 
ingto--10-sM,ofBGLtavidinto-2X 10m6M. 
Avidin blocked by an excess of biotin did not 
influence the KS, value of BGL, nor did biotin 
(fig.2). Changing the ligand:avidin molecular ratio 
from 4: 1 to 1: 1 did not seem to cause a correspond- 
ing change in the I&e value of BGL t avidin (fig.3). 
4. Discussion 
The control experiments with biotin-blocked 
avidin or biotin alone show that neither avidin nor 
s! loo1 I 
r 7 lo- 
M concentration of competing Ilgand 
Fig.2. Effect of biotin-blocked avidin or biotin alone on 
BGL displacement of (D-Ala*LeuS)-[3H]enkephalin: BGL 
(0); BGL + avidin 4: 1 (=); BGL + biotin-blocked avidin 4:5:1 
(a); BGL + biotin 4:s (0). 
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Fig.3. Lack of effect of changing ligand-avidin molecular 
ratio from 4: 1 to 1: 1 on BGL + avidin displacement of 
(D-AJaZLeu5)-[‘Hlenkephalin: BGL (0); BGL + avidin (4:l) 
(=); BGL + avidin 1: 1 (0). 
biotin interferes with (D-Ala2-LeuS)-[3H]enkephalin 
binding to receptors. 
The effect of different spacer lengths on receptor 
affinity in the presence of avidin suggests that the large 
avidin molecule (67 000 M,) disturbs the interaction 
of ligand with receptor and thus, that the receptor 
site is embedded in an environment that prevents close 
contact with the avidin-ligand complex. The fully 
extended lengths of the ligands are 22-27 A for BL 
and 30-35 A for BGL. The conformation of enke- 
phalin in solution is not well defined [9]. Little is 
known about the conformation necessary for receptor 
interaction of the enkephalin moiety; therefore it is 
hard to discuss molecular dimensions compatible w.ith 
formation of the sandwiches. Avidin allows interaction 
of biotin with its binding sites if it is connected to a 
bulky molecule by a spacer of X-9 A [s]. The length 
of lysine allows this interaction and a diglycine residue 
adds another 8-9 A. It might be possible to achieve 
even higher receptor affinity in the presence of avidin 
by increasing the spacer length, unless the secondary 
structure becomes unfavorable. The lack of effect of 
changing the 1igand:avidin ratio is of interest, one 
possible implication being that all the 4 ligands bound 
to one avidin molecule could interact with receptors 
assumed to be embedded in membranes. Four ligands 
should be able to bind simultaneously to avidin since 
studies of space-filling molecular models of the 
ligands gave a molecular radius of maximum 10 A, 
well below the 20 A allowed for simultaneous binding 
PI. 
The applicability of the described bifunctional 
ligands to affinity separation experiments remains to 
be tested. It may be necessary to use steady-state con- 
ditions since the receptor affinities are low in the 
presence of avidin. 
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